About A public-private partnership that supports the discovery of new medicines through open access research. About SGC Partners Research Laboratories SGC-Toronto SGC-UNC SGC-Frankfurt SGC-Karolinska SGC-Neuro SGC-UCL Governance Collaborators Open Science Equity, Diversity and Inclusion Impact Science and Resources Proteins Structure Gallery Expression Vectors Plasmids Constructs Production Protocols ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees ChemBioPort Chemical Probes Program CHEMICAL PROBES Donated chemical probes Chemical Handles Human Kinase Chemical Probe Program ANTIBODIES TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM Open Lab Notebooks PUBLICATIONS People Global Aled Edwards, CEO Susan McCormick, CFO Max Morgan, General Counsel and Public Policy Director SGC Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Takis Prinos Matthieu Schapira Levon Halabelian SGC UNC Tim Willson Alison Axtman David Drewry Peter J. Brown SGC UCL Mat Todd SGC Karolinska Michael Sundström SGC Frankfurt Stefan Knapp Susanne Müller-Knapp Thomas Hanke Vladimir Rogov Krishnal Saxena Andreas Joerger Václav Němec Andreas Krämer Sandra Röhm SGC Neuro Edward Fon Thomas Durcan Jean-François Trempe Ziv Gan-Or Peter McPherson Carl Laflamme Roxanne Lariviere News & Outreach News & Events News from SGC Press Releases Events Tweets by thesgconline
A public-private partnership that supports the discovery of new medicines through open access research.
A-485 A chemical probe for p300/CBPThis probe is available to purchase from Tocris, Cayman Chemical and Sigma. The control may be requested by clicking here. For any inquiries please contact proberequests@thesgc.org.group newOverview A-485 A-486 Abbvie has developed a potent acetyl-CoA competitive histone acetyltransferase (HAT) inhibitor of p300/CBP and has donated A-485 and its control A-486 to the SGC probe collection, following review of published data along SGC probe guidelines. A-485 is a potent and selective HAT inhibitor of p300/CBP in vitro with an IC50 of 10 nM in a p300 TR-FRET assay and 3 nM in a CBP TR-FRET assay with selectivity > 1000-fold over closely related HATs. SPR data indicates potent binding to p300 (KD=15 nM). In PC-3 cells A-485 reduces H3K27ac with IC50 of 73 nM while not affecting H3K9ac levels. Inhibition of cellular proliferation is observed in several cancer cell types, most notably AR+ prostate, multiple myeloma, and NHL. A-486 is a suitable control with 1000-fold higher IC50 in the p300 TR-FRET assay. Properties A-485 A-486 (Negative Control) Physical and chemical properties for A-485 Molecular weight 536.2 Molecular formula C25H24F4N4O5 IUPAC name N-(4-Fluorobenzyl)-2-{(1R)-5-[(methylcarbamoyl)amino]-2',4'-dioxo-2,3-dihydro-3'H-spiro[indene-1,5'-[1,3]oxazolidin]-3'-yl}-N-[(2S)-1,1,1-trifluoro-2-propanyl]acetamide MollogP 3.407 PSA 86.47 No. of chiral centres 2 No. of rotatable bonds 10 No. of hydrogen bond acceptors 9 No. of hydrogen bond donors 2 Physical and chemical properties for A-486 (Negative Control) Molecular weight 536.2 Molecular formula C25H24F4N4O5 MollogP 3.407 PSA 86.47 No. of chiral centres 2 No. of rotatable bonds 10 No. of hydrogen bond acceptors 9 No. of hydrogen bond donors 2 SMILES: A-485: C[C@@H](C(F)(F)F)N(Cc1ccc(cc1)F)C(CN1C([C@]2(CCc3cc(ccc23)NC(NC)=O)OC1=O)=O)=O A-486: C[C@@H](C(F)(F)F)N(Cc1ccc(cc1)F)C(CN1C([C@]2(CCc3ccc(cc23)NC(NC)=O)OC1=O)=O)=O InChI: A-485: InChI=1S/C25H24F4N4O5/c1-14(25(27,28)29)32(12-15-3-5-17(26)6-4-15)20(34)13-33-21(35)24(38-23(33)37)10-9-16-11-18(7-8-19(16)24)31-22(36)30-2/h3-8,11,14H,9-10,12-13H2,1-2H3,(H2,30,31,36)/t14-,24+/m0/s1 A-486: InChI=1S/C25H24F4N4O5/c1-14(25(27,28)29)32(12-15-3-6-17(26)7-4-15)20(34)13-33-21(35)24(38-23(33)37)10-9-16-5-8-18(11-19(16)24)31-22(36)30-2/h3-8,11,14H,9-10,12-13H2,1-2H3,(H2,30,31,36)/t14-,24+/m0/s1 InChIKey: A-485: VRVJKILQRBSEAG-LFPIHBKWSA-N A-486: MTTJOZOOUCZVHO-LFPIHBKWSA-N Cell-based Assay Data Analysis of high content microscopy shows that A-485 (but not A-486) decreases H3K27Ac (open squares), but not H3K9Ac (closed squares) levels after three hours of treatment in PC-3 cells. Error bars represent the s.d. of n = 3 independent biological replicates A-485 selectively inhibits production of p300 acetylation products H3K27Ac and H3K18Ac after three hours of treatment in PC-3 cells (n = 2). Co-crystal structures Please wait whilst the interactive viewer is loaded! Main features 1. Overall structure of Δp300 HAT domain with A-485 2. Overlay of Lys-CoA structure indicating A-485 binds in CoA site 3. Shape of A-485 binding pocket 4. Key interactions of the binding of A-485 to Δp300 HAT domain References Lasko, L., Jakob, C., Edalji, R., Qiu, W., Montgomery, D., & Digiammarino, E. et al. (2017). Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature, 550, 128-132. Weinert BT, Narita T, Satpathy S, Srinivasan B, Hansen BK, Schölz C, et al. (2018) Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome. Cell 174: 1-14.